Cholinesterase Inhibitors for Alzheimer's Disease: Multitargeting Strategy Based on Anti-Alzheimer's Drugs Repositioning

被引：100

作者：

Kabir, Md Tanvir ^{[1
]}

Uddin, Md Sahab ^{[2
,3
]}

Begum, Marium ^{[4
]}

Thangapandiyan, Shanmugam ^{[5
]}

Rahman, Md Sohanur ^{[6
]}

Aleya, Lotfi ^{[7
]}

Mathew, Bijo ^{[8
,9
]}

Ahmed, Muniruddin ^{[10
]}

Barreto, George E. ^{[11
]}

Ashraf, Ghulam Md ^{[12
,13
]}

机构：

[1] BRAC Univ, Dept Pharm, Dhaka, Bangladesh

[2] Southeast Univ, Dept Pharm, Dhaka, Bangladesh

[3] Pharmakon Neurosci Res Network, Dhaka, Bangladesh

[4] East West Univ, Dept Pharm, Dhaka, Bangladesh

[5] Bharathiar Univ, Dept Zool, Coimbatore, Tamil Nadu, India

[6] Univ Toyama, Grad Sch Innovat Life Sci, Toyama, Japan

[7] Bourgogne Franche Comte Univ, Chronoenvironm Lab, CNRS 6249, Besancon, France

[8] Ahalia Sch Pharm, Dept Pharmaceut Chem, Div Drug Design, Palakkad, India

[9] Ahalia Sch Pharm, Dept Pharmaceut Chem, Med Chem Res Lab, Palakkad, India

[10] Daffodil Int Univ, Dept Pharm, Dhaka, Bangladesh

[11] Univ Autonoma Chile, Inst Ciencias Biomed, Santiago, Chile

[12] King Abdulaziz Univ, King Fahd Med Res Ctr, Jeddah, Saudi Arabia

[13] King Abdulaziz Univ, Fac Appl Med Sci, Dept Med Lab Technol, Jeddah, Saudi Arabia

来源：

CURRENT PHARMACEUTICAL DESIGN | 2019年 / 25卷 / 33期

关键词：

Acetylcholine; acetylcholinesterase inhibitors; tacrine; donepezil; galantamine; rivastigmine; Alzheimer's disease; PLACEBO-CONTROLLED TRIAL; ACETYLCHOLINESTERASE INHIBITORS; SENILE PLAQUES; CLINICAL PHARMACOKINETICS; NEUROFIBRILLARY TANGLES; CHOLINERGIC HYPOTHESIS; BIOLOGICAL EVALUATION; COGNITIVE IMPAIRMENT; AMYLOID HYPOTHESIS; ASSESSMENT SCALE;

D O I：

10.2174/1381612825666191008103141

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

In the brain, acetylcholine (ACh) is regarded as one of the major neurotransmitters. During the advancement of Alzheimer's disease (AD) cholinergic deficits occur and this can lead to extensive cognitive dys-function and decline. Acetylcholinesterase (AChE) remains a highly feasible target for the symptomatic improvement of AD. Acetylcholinesterase (AChE) remains a highly viable target for the symptomatic improvement in AD because cholinergic deficit is a consistent and early finding in AD. The treatment approach of inhibiting peripheral AChE for myasthenia gravis had effectively proven that AChE inhibition was a reachable therapeutic target. Subsequently tacrine, donepezil, rivastigmine, and galantamine were developed and approved for the symptomatic treatment of AD. Since then, multiple cholinesterase inhibitors (ChEIs) have been continued to be developed. These include newer ChEIs, naturally derived ChEIs, hybrids, and synthetic analogues. In this paper, we summarize the different types of ChEIs which are under development and their respective mechanisms of actions.

引用

页码：3519 / 3535

页数：17

共 170 条

[1] Al-Mamun A, 2016, INT J ADV COMPUT SC, V7, P16
[2] Alva Gustavo, 2008, Psychiatry (Edgmont), V5, P27
[3] Recent progress in repositioning Alzheimer's disease drugs based on a multitarget strategy
Amelia Santos, M.
Chand, Karam
Chaves, Silvia
[J]. FUTURE MEDICINAL CHEMISTRY, 2016, 8 (17) : 2113 - 2142
[4] [Anonymous], 2017, J INTELLECT DISABIL, DOI DOI 10.6000/2292-2598.2017.05.02.3
[5] [Anonymous], 2016, J NEUROL NEUROPHYSIO, DOI DOI 10.4172/2155-9562.1000397
[6] [Anonymous], PRIM CARE COMPANION
[7] [Anonymous], 2019, Alzheimer's disease Facts and Figures 2019
[8] [Anonymous], 2018, HDB RES CRITICAL EXA
[9] [Anonymous], 2000, DIAGN STAT MAN MENT
[10] [Anonymous], 2016, Int Neuropsychiatric Disease J, DOI DOI 10.9734/INDJ/2016/26317

← 1 2 3 4 5 6 7 8 9 10 →